Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Meropenem/vaborbactam - Melinta Therapeutics

Drug Profile

Meropenem/vaborbactam - Melinta Therapeutics

Alternative Names: Carbavance™; Meropenem and vaborbactam; Meropenem trihydrate/vaborbactam; Meropenem/RPX-7009; RPX-2014/RPX-7009; RPX-7009/RPX-2014; Vabomere; Vaborem

Latest Information Update: 23 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rempex Pharmaceuticals
  • Developer Melinta Therapeutics; Menarini; Rempex Pharmaceuticals; US Department of Health and Human Services
  • Class Antibacterials; Pyrrolidines; Small molecules; Thienamycins
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Bacterial infections; Urinary tract infections
  • Registered Bacteraemia; Gram-negative infections; Intra-abdominal infections; Nosocomial pneumonia; Pyelonephritis
  • Phase III Pneumonia

Most Recent Events

  • 23 Jun 2022 Preregistration for Bacteraemia, Nosocomial pneumonia, Pyelonephritis, Intra-abdominal infections, and Urinary tract infections in China (IV), as of June 2022 (Menarini pipeline, June 2022)
  • 29 Apr 2021 Melinta Therapeutics enters into a license agreement with Hikma Pharmaceuticals for meropenem and vaborbactam in Middle East and North Africa (MENA)
  • 18 Apr 2020 Additional safety and efficacy data from the phase III TANGO 2 trial in Gram-negative infections presented at 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top